KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Receivables (2016 - 2025)

Biogen (BIIB) has 17 years of Receivables data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, Receivables fell 4.44% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $1.3 billion, down 4.44%, while the annual FY2025 figure was $1.3 billion, 4.44% down from the prior year.
  • Receivables reached $1.3 billion in Q4 2025 per BIIB's latest filing, up from $4.8 million in the prior quarter.
  • Across five years, Receivables topped out at $1.9 billion in Q1 2021 and bottomed at $3.9 million in Q1 2025.
  • Average Receivables over 5 years is $1.1 billion, with a median of $1.6 billion recorded in 2021.
  • Peak YoY movement for Receivables: tumbled 99.62% in 2023, then soared 8448.42% in 2025.
  • A 5-year view of Receivables shows it stood at $1.6 billion in 2021, then increased by 9.88% to $1.7 billion in 2022, then fell by 2.51% to $1.7 billion in 2023, then dropped by 15.58% to $1.4 billion in 2024, then dropped by 4.44% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $1.3 billion in Q4 2025, $4.8 million in Q3 2025, and $1.6 billion in Q2 2025.